Rigshospitalet
Copenhagen, Denmark
NCT Number: NCT06443255
When performed by trained personnel nasotracheal intubation is a safe and effective technique for attaining a secure airway in preparation for surgery of the head and neck. The procedure can be deemed necessary due to the nature of the surgical procedure or considerations in regard to the patient's comorbidities. For a certain group of patients with expected difficult airways, the procedure is done whilst they are awake and aided by fiberoptics.
For these awake patients, extra precautions must be taken to ensure the procedure is conducted with minimal pain and discomfort. The pain and discomfort arises from the mechanical manipulation of the nasal mucosa and can be alleviated in part by means of topical analgesia as well as through decongestion, providing more space within the nasal cavity. For these purposes, several drugs in varying combinations and dosages are used, but no single drug choice is universally recommended.
Cocaine is one of these appropriate drugs. It is a magistral formula used especially due to its unique combination of both vasoconstrictive and analgesic properties. Concerns have though been raised regarding cocaine's potential toxicity and alternative medications are continuously sought after.
A combination of lidocaine and xylometazoline can also be used for preparation of the nose prior to awake nasal fiberoptic intubation. Lidocaine contributes with its analgesic effect whilst xylometazoline functions as the vasoconstrictor.
The investigators wish to compare the analgesic effects of cocaine and lidocaine/phenylephrine to each other and saline when subjectively scored on a visual analogue scale of 0-100 mm immediately after simulated awake nasal intubation on healthy volunteers.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
Copenhagen, Denmark
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
2 mL of 4% cocaine
1.5 mL of 4% lidocaine
0.5 mL of xylometazoline 0.1%
2 mL of saline 0.9%
Time frame: Immediately following the procedure of 10 cm insertion of a 6.0 nasal endotracheal tube
Self reported pain on a visual analogue scale of 0-100 mm
Time frame: One minute after the procedure of insertion of a 6.0 nasal endotracheal tube
Self reported pain on a visual analogue scale of 0-100 mm
Time frame: 5 minutes before drug administration and 1, 3, 5, 7 and 9 minutes after drug administration
Volume within both nasal cavities measured with acoustic rhinometry
Time frame: Fiberoptic endoscopy performed 10 minutes before drug administraion and 10 minutes after drug administration
Preferred nasal cavity based on a comparison of the degree of vasoconstriction of the nasal mucosa evaluated by fiberoptic endoscopy assessed by ENT-specialist
Time frame: 15 minutes before drug administration and 1, 2 and 3 hours after drug administration
Concentraion of cocaine and cocaine's main metabolite benzoylecgonine in blood and saliva samples respectively
Time frame: 5 minutes before drug administration and 1, 2, 3, 4 and 5 minutes after drug administration
Measurement of heart rate
Time frame: 5 minutes before drug administration and 1, 2, 3, 4 and 5 minutes after drug administration
Measurement of mean arterial blood pressure
Time frame: 15 minutes after drug administration
The degree of discomfort and unpleasentness of taste of the drug administration on a scale of 1-10 and whether they felt exaltation after drug administration.
Rigshospitalet, Denmark
Other
Comparison of Cocaine, Lidocaine/xylometazoline and Saline for Intranasal Analgesia - a Blinded Triple Crossover Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05999734
Agnosia, Analgesia
Tanta, Gharbia Governorate, Egypt
View Trial DetailsNCT02471898
Agnosia, Analgesia
Pasadena, California, United States
View Trial DetailsNCT06675916
Agnosia, Analgesia
Villeurbanne, France
View Trial DetailsNCT05250492
Agnosia, Analgesia
Lanester, France
View Trial Details